Michelle McBride
Psychiatric/Mental Health · Cincinnati, OHNPI 1699291534
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $18,725 of the $29,156 with a category attached, or 64.2%. AbbVie accounts for 71.0% of it on its own, with 22 other manufacturers making up the rest. Among psychiatric/mental health clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 686 payments — averaging $42.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$21K
- Johnson & Johnson$2K
- Otsuka America Pharmaceutical, Inc.$1K
- Alkermes, Inc.$1K
- Lundbeck LLC$721
- Supernus Pharmaceuticals, Inc.$653
- plus $3K from 17 others
What the payments were for
- Speaking & faculty fees$18,72564%
- Travel & lodging$2811%
- Food & beverage$10,09135%
- Education$580%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 162 | $20,711 |
| Johnson & Johnson | 55 | $1,676 |
| Otsuka America Pharmaceutical, Inc. | 82 | $1,289 |
| Alkermes, Inc. | 104 | $1,201 |
| Lundbeck LLC | 63 | $721 |
| Supernus Pharmaceuticals, Inc. | 50 | $653 |
| Neurocrine Biosciences, Inc. | 32 | $590 |
| Teva Pharmaceuticals USA, Inc. | 33 | $552 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 19 | $365 |
| E.r. Squibb & Sons, L.L.C. | 22 | $307 |
| Sunovion Pharmaceuticals Inc. | 26 | $249 |
| Vanda Pharmaceuticals Inc. | 9 | $180 |
| Axsome Therapeutics, Inc. | 4 | $163 |
| Idorsia Pharmaceuticals US Inc | 3 | $142 |
| Indivior Inc. | 6 | $95 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $73 |
| Merck | 3 | $46 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $35 |
| Corium, LLC | 2 | $34 |
| Almatica Pharma LLC | 1 | $20 |
| Alcresta Therapeutics, Inc. | 1 | $19 |
| GSK | 1 | $18 |
| Neos Therapeutics, LP | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$19,184
- LYBALVI$974
- INVEGA SUSTENNA$612
- ABILIFY MAINTENA$244
- ABILIFY ASIMTUFII$244
- INVEGA TRINZA$243
- SPRAVATO$150
- QELBREE$124
- QUVIVIQ$122
- REXULTI$120
- COBENFY$118
- CAPLYTA$112
- INGREZZA$100
How this compares
$29,156 in reported general payments places this provider in the 95th percentile of 1,808 psychiatric/mental health providers in Ohio.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 29 | $251,002 |
| Invega SustennaPaliperidone Palmitate | 78 | $223,092 |
| AustedoDeutetrabenazine | 26 | $152,850 |
| Invega TrinzaPaliperidone Palmitate | 16 | $150,038 |
| RexultiBrexpiprazole | 71 | $123,133 |
| Abilify AsimtufiiAripiprazole | 21 | $115,428 |
| VraylarCariprazine Hcl | 54 | $80,571 |
| Abilify MaintenaAripiprazole | 26 | $76,700 |
| CaplytaLumateperone Tosylate | 17 | $27,406 |
| FetzimaLevomilnacipran Hcl | 17 | $20,459 |
| Aripiprazole | 52 | $14,336 |
| BelsomraSuvorexant | 27 | $11,805 |
| Fluphenazine Hcl | 20 | $11,097 |
| Olanzapine OdtOlanzapine | 79 | $10,666 |
| Paliperidone ErPaliperidone | 32 | $8,670 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Invega Trinza | $1,676 | $373,13094 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Asimtufii, Abilify Maintena | $1,289 | $315,261118 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $590 | $251,00229 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $552 | $152,85026 claims |
| AbbVieVraylar, Fetzima | $20,711 | $101,02971 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $365 | $27,40617 claims |
| MerckBelsomra | $46 | $11,80527 claims |
| Almatica Pharma LLCSertraline Hcl | $20 | $60095 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,808 psychiatric/mental health providers in Ohio.
Other psychiatric/mental health in Cincinnati
- Seth FramptonCincinnati$10K
- Crystal TravisJackson$333K
- Kristina RoweIronton$253K
- Patricia SparksPortsmouth$210K
- Mary HallWarren$195K
- Kassandra KornbauCanfield$170K
- Steven MatesDayton$121K
- Robert ParsonsYoungstown$119K
- Chriscia BaneChillicothe$115K
- Rachael McLaughlinMaple Heights$114K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.